In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott cuts prices to VHA under renegotiated sole-source contract, adds Carpuject syringe to agreement.

This article was originally published in The Gray Sheet

Executive Summary

ABBOTT/VHA SUPPLY DEAL RENEGOTIATED IN RESPONSE TO PRICING PRESSURE for intravenous supplies and other products covered under the contract. Abbott's existing sole-source deal with VHA was set to expire in 1999, but VHA renegotiated the agreement in light of lower prices in markets covered by the deal. The supply pact includes I.V. supplies, parenteral nutritionals and compounding systems, electronic drug delivery systems, critical care products, and injectable drugs and delivery systems.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts